How have ABOS and CUE total returns compared?

Over the past 5 years, ABOS delivered -32.60% and CUE delivered -42.42% annualized total return. Past performance doesn't predict future results.

Acumen Pharmaceuticals, Inc. (ABOS) vs Cue Biopharma, Inc. (CUE)

A side-by-side comparison of Acumen Pharmaceuticals, Inc. and Cue Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ABOS

Acumen Pharmaceuticals, Inc.

$144M

$2.00HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT

CUE

Cue Biopharma, Inc.

$171M

$23.51HealthcareDelayed quote: Oct 6, 2026, 10:34 AM EDT

Total return — ABOS vs CUE

growth of $100 · dividends reinvested · last 5y

ABOS -89.4% (-36.2%/yr)CUE -93.0% (-41.3%/yr)ABOS compounded faster over this window

ABOS CUE

ABOS vs CUE: by the numbers

•CUE is the larger company ($171M vs $144M market cap).
•Both run net losses; ABOS's is the smaller (0.00% vs -435.83% net margin).

Metrics side by side

Valuation

Metric	ABOS	CUE
P/S ratio	N/A	4.54
P/B ratio	2.52	73.93

Profitability

Metric	ABOS	CUE
Gross margin	0.00%	99.69%
Operating margin	0.00%	-96.56%
Net margin	0.00%	-435.83%
ROE	-183.44%	-7104.24%
ROIC	-118.67%	-1039.56%

Growth (annualized)

Metric	ABOS	CUE
Revenue CAGR (5Y)	N/A	47.08%
Total return CAGR (5Y)	-32.60%	-42.42%

Frequently asked

How have ABOS and CUE total returns compared?: Over the past 5 years, ABOS delivered -32.60% and CUE delivered -42.42% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ABOS analysis Full CUE analysis Interactive comparison tool

Dig into the metrics

Acumen Pharmaceuticals ROE Cue Biopharma ROE Acumen Pharmaceuticals operating margin Cue Biopharma operating margin Acumen Pharmaceuticals revenue growth Cue Biopharma revenue growth Acumen Pharmaceuticals free cash flow Cue Biopharma free cash flow

Acumen Pharmaceuticals & Cue Biopharma appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.